During the past 40 years, cytokines and cytokine receptors have been extensively
investigated as either cancer targets or cancer treatments. A strong preclinical rationale …

Abstract Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging.
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …

Ovarian cancer encompasses a heterogeneous group of malignancies that involve the
ovaries, fallopian tubes and the peritoneal cavity. Despite major advances made within the …

The tumor microenvironment evolves during malignant progression, with major changes in
nonmalignant cells, cytokine networks, and the extracellular matrix (ECM). In this study, we …

Recent studies have shown that the tumor extracellular matrix (ECM) associates with
immunosuppression, and that targeting the ECM can improve immune infiltration and …

High-grade serous ovarian carcinoma (HGSOC) is a cancer with dismal prognosis due to
the limited effectiveness of existing chemo-and immunotherapies. To elucidate mechanisms …

Following a period of slow progress, the completion of genome sequencing and the
paradigm shift relative to the cell of origin for high grade serous ovarian cancer (HGSOC) led …

Platinum resistant ovarian cancer, usually defined as progression occurring within 6 months
after completing platinum-based therapy, is a heterogeneous disease with poor prognosis …

Ovarian cancer has the highest mortality of all of the gynecological malignancies. There are
several distinct histotypes of this malignancy characterized by specific molecular events and …

Simple Summary Ovarian cancer is a lethal disease in women with a 10-year survival rate
of< 40% worldwide. A key molecular alteration in ovarian cancer is the aberrant …